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Spinocerebellar ataxias (SCAs) are a genetically heterogeneous group of neurodegenerative disorders sharing atrophy
of the cerebellum as a common feature. SCA1 and SCA2 are two ataxias caused by expansion of polyglutamine tracts in
Ataxin-1 (ATXN1) and Ataxin-2 (ATXN2), respectively, two proteins that are otherwise unrelated. Here, we use a
Drosophila model of SCA1 to unveil molecular mechanisms linking Ataxin-1 with Ataxin-2 during SCA1 pathogenesis.
We show that wild-type Drosophila Ataxin-2 (dAtx2) is a major genetic modifier of human expanded Ataxin-1 (Ataxin-
1[82Q]) toxicity. Increased dAtx2 levels enhance, and more importantly, decreased dAtx2 levels suppress Ataxin-
1[82Q]-induced neurodegeneration, thereby ruling out a pathogenic mechanism by depletion of dAtx2. Although
Ataxin-2 is normally cytoplasmic and Ataxin-1 nuclear, we show that both dAtx2 and hAtaxin-2 physically interact with
Ataxin-1. Furthermore, we show that expanded Ataxin-1 induces intranuclear accumulation of dAtx2/hAtaxin-2 in both
Drosophila and SCA1 postmortem neurons. These observations suggest that nuclear accumulation of Ataxin-2
contributes to expanded Ataxin-1-induced toxicity. We tested this hypothesis engineering dAtx2 transgenes with
nuclear localization signal (NLS) and nuclear export signal (NES). We find that NLS-dAtx2, but not NES-dAtx2, mimics
the neurodegenerative phenotypes caused by Ataxin-1[82Q], including repression of the proneural factor Senseless.
Altogether, these findings reveal a previously unknown functional link between neurodegenerative disorders with
common clinical features but different etiology.
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Introduction
Inherited ataxias are a genetically heterogeneous group of
neurodegenerative diseases characterized by loss of motor
coordination and balance. They can be caused by loss-of-
function or gain-of-function mechanisms; some ataxias are
triggered by missense mutations, while others by triplet
repeat expansions, which may occur either in coding or non-
coding sequences. Furthermore, the gene products impli-
cated in the different ataxias do not share obvious functional
or structural relationships to each other. In spite of this
genetic heterogeneity, many ataxias show striking similarities.
In particular, it is often difﬁcult to distinguish between
Spinocerebellar ataxias (SCAs) based only on clinical and
pathological observations, and their differential diagnosis
often requires genetic testing. In addition, a common
neuropathological feature of SCAs is the atrophy of the
cerebellar module (reviewed in [1–3]). These similarities
suggest that SCAs, and perhaps other ataxias, may also share
common mechanisms of pathogenesis. In support of this
hypothesis a recent study reported a network of physical
protein-protein interactions among many factors associated
with ataxia and Purkinje cell degeneration in humans and
mice [4]. However, no speciﬁc molecular mechanisms are
known that can account for the clinical and neuoropatho-
logical similarities among SCAs and other ataxias.
SCA1 is caused by the expansion of a CAG repeat encoding
a polyglutamine tract in the protein Ataxin-1 that induces a
toxic gain of function [5]. The expanded protein accumulates
in neuronal nuclear inclusions (NIs) that also contain tran-
scription factors, chaperones, proteasome subunits, and
other components of the protein quality control/degradation
machinery like CHIP or Ataxin-3 [6–11]. Abnormally long
polyglutamine tracts are the common cause of pathogenesis
in at least ﬁve other SCAs (SCA2, 3, 6, 7 and 17) and three
additional neurodegenerative diseases including Hunting-
ton’s disease (HD) [1,12]. Protein quality control machinery as
well as transcriptional dysregulation are general mechanisms
that have been implicated in the pathogenesis of these
polyglutamine disorders [13–15].
Although the polyglutamine expansion triggers the toxicity
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models have shown that protein context plays a key role in
expanded Ataxin-1-induced neurodegeneration (reviewed in
[15]). The nuclear localization signal[16] and phosphoryla-
tion[17] inﬂuence the toxicity of expanded Ataxin-1. In
addition, certain interacting partners of unexpanded Ataxin-
1 are critical to expanded Ataxin-1 toxicity [9,18,19]. In this
context, expanded Ataxin-1 was recently found to induce a
decrease in the levels of Senseless (Sens) and its murine
orthologue growth factor independent 1 (Gﬁ1) [18]. These are
transcription factors that interact with unexpanded Ataxin-1
and are necessary for Purkinje cell survival in mice [18] and
for sensory organ development in Drosophila [20]. The
importance of the protein framework has also been shown
in models of other polyglutamine diseases [15,21].
Genetic screening in Drosophila models of neurodegener-
ative diseases is a powerful approach to identify modiﬁer
genes and pathways implicated in pathogenesis [22–24]. We
previously reported an unbiased genetic screen with a
Drosophila model of SCA1 [25]. Here we report the identi-
ﬁcation of the Drosophila homolog of Ataxin-2 (dAtx2)a sa
major modiﬁer of expanded Ataxin-1-induced toxicity.
Ataxin-2 is a widely expressed cytoplasmic protein with no
similarity to Ataxin-1 except for the polyglutamine domain.
The normal function of Ataxin-2 remains unclear, although it
has been implicated in mRNA processing [26–28] and
translational regulation in yeast [29,30], C. elegans[31] and
Drosophila[32], where it is also required for actin ﬁlament
formation [33]. However, expansion of its polyglutamine
domain leads to SCA2 [34–36]. The functional interactions
between Ataxin-1 and Ataxin-2 described here mechanisti-
cally tie these two proteins and point to previously unknown
pathogenic links between two inherited ataxias.
Results
Increased/Reduced Levels of Ataxin-2 Enhance/Suppress
Expanded Ataxin-1 Toxicity in the Drosophila Eye
Expression of Ataxin-1[82Q] in the eye of SCA1
82Q ﬂies
causes external and internal abnormal phenotypes [25].
Externally, the eyes of these animals show severe ommatidial
disorganization as well as interommatidial bristle loss when
compared with control eyes (Figure 1, compare A and A9 with
B and B9). Internally, examination of the retina reveals tissue
loss and shortened and curved photoreceptor neurons
(Figure 1, compare F with G). In a screen for genetic
modiﬁers of Ataxin-1[82Q]-induced toxicity we recovered
EP(3)3145 as an enhancer of the eye phenotype (data not
shown). This is an insertion of an EP transposable element
[37] in the 59 end of dAtx2, the Drosophila orthologue of human
Ataxin-2. The Drosophila and human proteins share 23%
amino acid identity and 36% amino-acid similarity over the
entire protein with the most conserved sequences corre-
sponding to the ATX2-N and ATX2-C domains (43% and
62% identity, respectively) [33]. Molecular analysis revealed
that the EP element is inserted 3121 bp upstream of the ATG
and in the same orientation as the dAtx2 transcription unit
(data not shown and [33]). These data suggested that
EP(3)3145 over-expresses the dAtx2 transcription unit to
enhance the SCA1
82Q eye phenotype. As described below, this
possibility was conﬁrmed using a transgene that over-
expresses the dAtx2 cDNA.
Co-expression of a wild-type dAtx2 transgene (dAtx2
OE)a t
low levels enhances the Ataxin-1[82Q]-induced eye pheno-
type. Externally, the eyes of SCA1
82Q/dAtx2
OE animals show no
bristles and increased ommatidial disorganization when
compared with the eyes of SCA1
82Q controls (compare Figure
1D and D9 with B and B9). Internally, photoreceptor cells are
considerably shorter (compare Figure 1I with G). Expression
of the same low levels of dAtx2 alone in the eye causes
relatively mild external disorganization and reduction of the
retinal width (Figure 1E, E9 and J). Overexpression of dAtx2
from EP(3)3145 and UAS-dAtx2 also aggravates the pheno-
types of other ﬂy models of neurodegenerative diseases
besides SCA1 [38,39]. However, since overexpression of dAtx2
causes an eye phenotype by itself (Figure 1E, E9 and J) and it is
toxic in many other tissues [33], it is difﬁcult to make strong
conclusions about the speciﬁcity of these genetic interactions.
To test the speciﬁcity of the genetic interaction, we
investigated if decreasing the levels of endogenous dAtx2
modiﬁes expanded Ataxin-1-induced toxicity. For this, we
used a 1.4 kb deletion in the dAtx2 locus (dAtx2
X1) that
removes part of the dAtx2 promoter, the ATG codon and
extends into the ﬁrst intron [33]. We ﬁnd that ﬂies expressing
Ataxin-1[82Q] and heterozygous for the dAtx2
X1 mutant allele
show a strong suppression of the eye phenotype, with much
improved arrangement of the ommatidia and bristles
compared to eyes from ﬂies expressing Ataxin-1[82Q] with
normal dAtx2 levels (compare Figure 1C and C9 with B and
B9). This suppression is also evident in the retinas of SCA1
82Q/
dAtx2
X1 ﬂies that show elongated photoreceptors and very
little tissue loss (compare Figure 1H with G). To further test
the speciﬁcity of this interaction, and to exclude potential
genetic background artefacts, we asked whether adding back
dAtx2 to SCA1
82Q/dAtx2
X1 ﬂies eliminates the suppression
effect. Figure S1 shows that SCA1
82Q/dAtx2
X1/dAtx2
OE ﬂies
show an eye phenotype that is very similar to the phenotype
of SCA1
82Q ﬂies. The effects of the dAtx2
X1 and dAtx2
OE alleles
decreasing/increasing dAtx2 levels are demonstrated in
Figure S2.
Since dAtx2 is an RNA binding protein, we investigated if
the observed suppression of Ataxin-1[82Q] toxicity was the
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Author Summary
The spinocerebellar ataxias (SCAs) are a group of ;30 neuro-
degenerative disorders caused by different types of mutations in a
variety of unrelated genes. For example, SCA1 and SCA2 are caused
by mutations in Ataxin-1 and Ataxin-2, two proteins related in name
only. Despite these differences, most SCAs share a number of
striking clinical and neuropathological similarities, such as ataxia,
tremor, speech difficulties, and atrophy of the cerebellum and
brainstem. In addition, many ataxia-causing proteins share interact-
ing protein partners. Together, these observations suggest that
many SCAs also share common mechanisms of pathogenesis. Here,
we report previously unknown functional interactions between the
genes and proteins responsible for SCA1 and SCA2. We find that
Ataxin-1 and Ataxin-2 physically interact, and that mutant Ataxin-1
forces Ataxin-2 to accumulate in the nucleus instead of the
cytoplasm. Most importantly, using an animal model, we discovered
that the Drosophila Ataxin-2 gene is a strong suppressor of Ataxin-1-
induced neurotoxicity. Thus, neuronal degeneration may take place
through common mechanisms in different SCAs. These findings
open the possibility of future common therapies for these neuro-
degenerative disorders for which there is no effective treatment.result of dAtx2 affecting the levels of the SCA1
82Q mRNA
transcript or the levels of Ataxin-1 [82Q] protein. As shown in
Figure 1K and L neither the levels of SCA1
82Q mRNA nor the
levels of the Ataxin-1[82Q] protein are affected by changing
the levels of dAtx2.
Reduced Levels of Ataxin-2 Suppress Expanded Ataxin-1-
Induced Neuronal Dysfunction in Drosophila
To verify that the genetic interaction between Ataxin-1 and
dAtx2 is not limited to the eye, we analyzed the effect of
altering dAtx2 levels on expanded Ataxin-1-induced neuro-
nal dysfunction.
The motor performance of ﬂies as a function of age can be
quantiﬁed using a climbing assay [40]. This assay has been
used to analyze the effects of toxic proteins on neurons in
other Drosophila models of neurodegenerative diseases [41,42].
Control ﬂies show no signiﬁcant decrease in their motor
performance until late in life. Figure 2A shows that ;74% of
control ﬂies still climb after thirty-six days (black triangles).
Flies expressing Ataxin-1[82Q] speciﬁcally in the nervous
system (using nrv2-GAL4) display a progressive impairment of
their motor performance (Figure 2A, blue circles). In the
context of the Drosophila life span, this is a late onset and
progressive phenotype as compared to the performance of
control ﬂies in the same period of time. We then analyzed the
Figure 1. dAtx2 Levels Modulate Ataxin-1[82Q]-Induced Eye Neurotoxicity
(A–E, A9–E9) Scanning electron microscopy (SEM) eye images and (F–J) retinal paraffin sections of eyes from the genotype combinations indicated on
the top. Arrows indicate photoreceptor length. Transgenes are expressed form the gmr-GAL4 eye driver.
(A, F) Control eyes show regularly arranged ommatidia, and evenly distributed interommatidial bristles (A). Control retinas have long, straight
photoreceptors with no gaps (F).
(B, G) SCA1
82Q eyes have disorganized ommatidia and interommatidial bristles are unevenly distributed or missing (compare B and A). SCA1
82Q retinas
show fewer photoreceptors that are shortened and curved (compare G with F).
(C, H) Suppression of external and retinal degeneration in SCA1
82Q flies with decreased dAtx2 levels (SCA1
82Q/dAtx2
X1). Note the regular arrangement of
the ommatidia in SCA1
82Q/dAtx2
X1 animals when compared to SCA1
82Q eyes with normal levels of dAtx2 (compare C with B). Note also the improved
retinal organization with longer straight photoreceptors (compare H with G).
(D, I) Eyes co-expressing Ataxin-1[82Q] and wild type dAtx2 (SCA1
82Q/dAtx2
OE) have more disorganized ommatidia when compared to SCA1
82Q alone.
Note the absence of bristles (compare D with B). In addition, photoreceptors are shorter and more degenerated (compare I with H).
(E, J) Eyes overexpressing low levels of dAtx2 (dAtx2
OE) show mild ommatidial disorganization, with few missing bristles (compare E with A). Internally,
photoreceptor cells are shortened (compare J with F). A-E flies were raised at 278C and F-J at 258C.
(K) Semiquantitative RT-PCR revealing the levels of SCA1
82Q messenger RNA in flies with different levels of dAtx2.
(L) Western blot analysis revealing the levels of Ataxin-1[82Q] protein in flies with different levels of dAtx2.
Genotypes: (A–J): Control: yw/þ; gmr-GAL4/UAS-LacZ. SCA1
82Q: UAS- SCA1
82Q [F7]/yw; gmr-GAL4/þ. SCA1
82Q/dAtx2
X1: SCA1
82Q [F7]/yw; gmr-GAL4/þ;
dAtx2
X1/þ. SCA1
82Q/ dAtx2
OE: UAS-SCA1
82Q [F7]/yw; gmr-GAL4/UAS- dAtx2 [4]. dAtx2
OE: gmr-GAL4/UAS- dAtx2 [4]. (A–E) SEM scale bar¼100lm. (A9–E9) are
30lmX3 0 lm. (F–J) scale bar¼10lm.
doi:10.1371/journal.pgen.0030234.g001
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Ataxin-1 and Ataxin-2 Interactionseffect of decreased levels of dAtx2 on the climbing phenotype
caused by Ataxin-1[82Q]. As shown in Figure 2A (red squares)
in SCA1
82Q ﬂies also heterozygous for the dAtx2
X1 mutation
climbing performance is signiﬁcantly improved compared to
ﬂies with normal dAtx2 levels (p,0.0001 for repeated
measures anova (rma) between genotypes). Figure 2A show
that while all SCA1
82Q animals fail to climb after 26 days,
SCA1
82Q/ dAtx2
X1 ﬂies continue to climb until later in life.
Thus the impairments in motor performance caused by
neuronal expression of Ataxin-1[82Q] are suppressed by
decreased dAtx2 levels.
We also studied the effect of Ataxin-1[82Q] expression in a
life span assay. Figure 2B shows that expression of Ataxin-
1[82Q] in the nervous system leads to premature death in
SCA1
82Q ﬂies in comparison to GFP controls (Figure 2B,
compare blue circles with black triangles). While SCA1
82Q
animals do not survive past 30 days, this early lethality
phenotype is suppressed in SCA1
82Q/ dAtx2
X1animals (Figure
2B, red squares).
Decreased Levels of dAtx2 Do Not Suppress
Neurodegeneration Caused by Expanded Huntingtin
To investigate whether dAtx-2 also modulates neurodegen-
eration in other models of polyglutamine disease, we tested
the effect of altering the dAtx2 levels in a Drosophila model of
Huntington’s disease [7,43]. Adult ﬂies expressing an ex-
panded N-terminal fragment of human huntingtin (N-
Htt
128Q) in the eye show a progressive retinal degeneration
which becomes obvious at day 5 after eclosion [7]. N-Htt
128Q
retinas show disorganized and missing photoreceptors
(Figure 2D, compare with control in 2C). N-Htt
128Q ﬂies also
overexpressing dAtx2 present a more degenerated retina
than ﬂies expressing N-Htt
128Q with normal levels of dAtx2
(data not shown). However, since overexpression of dAtx2 is
Figure 2. Specificity of the dAtx2/ Ataxin-1 Interaction
(A, B) Reduced levels of dAtx2 also suppress Ataxin-1[82Q]-induced motor dysfunction and shortened life span.
(A) Motor performance quantification in flies of the indicated genotypes measured as climbing ability as a function of age. Control animals expressing
just GFP perform well in the motor assay for 36 days (nrv2.GFP, black triangles), as do flies that are heterozygous for the dAtx2
X1 allele (nrv2.GFP/
dAtx2
X1, green diamonds). Flies expressing Ataxin-1[82Q] in the nervous system show progressive motor dysfunction when compared with controls
(nrv2. SCA1
82Q, blue circles). All nrv2. SCA1
82Q flies stop climbing after ;23 days. Flies expressing Ataxin-1[82Q] in the nervous system but with
decreased dAtx2 levels show improved motor performance (nrv2. SCA1
82Q/dAtx2
X1, red squares). Error bars represent standard deviation. Flies were
raised at 278C.
(B) Survivorship in flies of indicated genotypes. Control flies (nrv2.GFP, black triangles) do not show significant mortality during the first 30 days
(nrv2.GFP, black triangles). Expression of Ataxin-1 [82Q] in the nervous system leads to early mortality (nrv2. SCA1
82Q, blue circles). This phenotype is
suppressed by decreasing the levels of dAtx2 (nrv2. SCA1
82Q/dAtx2
X1, red squares).
(C–F) Reduced levels of dAtx2 do not suppress eye neurotoxicity or motor impairments caused by N-Htt
128Q.
(C–E) Expression of N-Htt
128Q in the eye leads to retinal degeneration and loss of photoreceptors and other cell types (compare D with control shown in
C). This eye phenotype is not altered in animals with reduced levels of dAtx2 (compare D and E).
(F) Expression of N-Htt
128Q in the nervous system leads to progressive motor dysfunction (nrv2. N-Htt
128Q, red), and decreasing the levels of dAtx2 does
not significantly suppress this phenotype (nrv2. N-Htt
128Q/dAtx2
X1, blue)
Genotypes: (A–B): nrv2.GFP: nrv2-GAL4/UAS-eGFP. nrv2.GFP/dAtx2
X1: nrv2-GAL4/UAS-eGFP; dAtx2
X1/þ. nrv2. SCA1
82Q: nrv2-GAL4/þ; UAS-SCA1
82Q
[M6]/þ. nrv2. SCA1
82Q/dAtx2
X1: nrv2-GAL4/þ; UAS-SCA1
82Q [M6]/dAtx2
X1. (C) yw; gmr-GAL4/UAS-GFP. (D) yw; gmr-GAL4/þ; UAS-N-Htt
128Q/þ. (E) yw; gmr-
GAL4/þ; UAS-N-Htt
128Q/dAtx2
X1. (F) nrv2.N-Htt
128Q: nrv2-GAL4/þ; UAS-N-Htt
128Q/þ. nrv2.N-Htt
128Q/dAtx2
X1: nrv2-GAL4/þ; UAS-N-Htt
128Q/ dAtx2
X1.
doi:10.1371/journal.pgen.0030234.g002
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Ataxin-1 and Ataxin-2 Interactionssufﬁcient to cause retinal degeneration (Figure 1J), this result
is not conclusive by itself. Therefore, we tested the effect of
decreasing dAtx2 levels on the N-Htt
128Q induced retinal
degeneration. As shown in Figure 2D-E, decreasing the levels
of dAtx2 (N-Htt
128Q/dAtx2
X1) does not obviously alter degen-
eration induced by N-Htt
128Q in the Drosophila eye.
We also investigated a possible genetic interaction between
dAtx2 and N-Htt
128Q in the motor performance assay
described above. Like with Ataxin-1[82Q], expression of N-
Htt
128Q in the nervous system leads to motor performance
impairments (Figure 2F) where N-Htt
128Q animals stop
climbing before day 20. The climbing performance of animals
expressing N-Htt
128Q with decreased levels of dAtx2 (N-
Htt
128Q/dAtx2
X1) is not signiﬁcantly different from that of
animals expressing N-Htt
128Q with normal levels of dAtx2
(Figure 2F). Therefore decreasing the levels of dAtx2 fails to
suppress N-Htt
128Q induced degeneration both in the retina
and in the nervous system.
Ataxin-2 Levels Modulate Expanded Ataxin-1-Induced
Loss of Mechanoreceptors Caused by Loss of Senseless
Protein
Senseless (Sens) is a proneural factor that is expressed and
required in the sensory organ precursor (SOP) cells of the
peripheral nervous system [20]. Expression of high levels of
Ataxin-1[82Q] in the thoracic SOPs using scabrous-GAL4 (sca-
GAL4) leads to a reduction in Sens protein levels in these cells
and loss of large mechanoreceptors (macrochaetae) in the
thorax of adult ﬂies [18]. Therefore, scoring adult thoracic
macrochaetae in SCA1
82Q animals provides a quantitative
phenotype with a known molecular foundation.
We analyzed the effect of altering Ataxin-2 levels on
Ataxin-1[82Q]-induced loss of mechanoreceptors. This was
performed by quantifying the number of macrochaetae in the
adult thorax of SCA1
82Q animals with different levels of
dAtx2. Using a relatively low expressing Ataxin-1[82Q] line,
we deﬁned conditions in which sca-GAL4-mediated expres-
sion in the SOP cells causes only 9% of macrochaetae loss
(Figure 3A-column-3 and Fig 3C, compare to controls Figure
3A-column-1 and Figure 3B). Expression of wild-type dAtx2
alone (dAtx2
OE) leads to no loss of machrochaetae (Figure 3A-
column-2 and Figure 3D), but co-expression of dAtx2 and
Ataxin-1[82Q] (SCA1
82Q/dAtx2
OE) leads to a severe loss of
macrochaetae compared to Ataxin-1[82Q] alone (Figure 3E,
compare with Figure 3C). Quantiﬁcation shows an ;80%
decrease in the number of macrochaetae when both proteins
are co-expressed compared to controls (Figure 3A-columns
1–4, p,0.0001, Tukey-Kramer HSD).
In the wing imaginal disc, Sens expression includes the
precursors of the large thoracic mechanoreceptor bristles,
and the two parallel rows of bristles at each side of the wing
margin (Figs. 3F-G). We quantiﬁed the amount of ﬂuores-
cence detected after anti-Sens immunostaining in wing
margin cells expressing Ataxin-1[82Q] with normal or
increased levels of dAtx2. Expression of either low levels of
Ataxin-1[82Q] or dAtx2 with sca-Gal4 (at 25C) produces no
detectable decrease in the levels of Sens in the wing margin
(Figure 3H and I compare with G and quantiﬁcation in K).
However co-expression of both Ataxin-1[82Q] and dAtx2 in
the same conditions induces a strong decrease in the levels of
Sens (Figure 3J). Quantiﬁcation of the Sens signal in SCA1
82Q/
dAtx2
OE animals (Figure 3K, fourth column) reveals a decrease
of ;50% in the amount of Sens signal when compared to
either wild type, SCA1
82Q or dAtx2
OE controls (p,0.001,
Tukey-Kramer HSD).
In addition, we investigated the consequences of decreasing
the amount of dAtx2 (using the dAtx2
X1 allele) in conditions
where Ataxin-1[82Q] reduces Sens levels in the wing margin
(i.e. at 278Ca n d2 9 8C). However, we did not detect a
signiﬁcant modiﬁcation (data not shown). Since it is possible
that we are not able to detect small changes on Sens levels in
wing discs from late third instar larvae, or this changes might
happen later in the SOP development, we also investigated
the effect of decreasing the amount of Ataxin-2 on Ataxin-
1[82Q]-induced mechanoreceptor loss. Expression of Ataxin-
1[82Q] at high levels (278C) in the SOP cells results in the loss
of ;20% of thoracic macrochaetae when compared to
controls (Figure 3L compare columns 1 and 2 p,0.0001,
Tukey-Kramer HSD; see Figure 3M). Reducing the levels of
endogenous dAtx2 with the heterozygous dAtx2
X1 mutation
partially rescues the Ataxin-1[82Q]-induced bristle pheno-
type. Loss of macrochaetae in SCA1
82Q/ dAtx2
X1 animals is
approximately half of that seen in animals with normal levels
Ataxin-2 (Figure 3L, compare columns 2 and 3 p,0.005,
Tukey-Kramer HSD, and see Figure 3N).
Physical Interaction between Human Expanded Ataxin-1
and Ataxin-2 Proteins
To further characterize the interactions between Ataxin-1
and Ataxin-2, we investigated possible protein-protein inter-
actions. Lysates from cells expressing Drosophila or human
Ataxin-2andGST-Ataxin-1[82Q]weresubjectedtoco-afﬁnity
puriﬁcation (co-AP) glutathione-S-transferase (GST) pull-
down assays. As shown in Figure 4A (lanes 1 and 2) and Figure
4B (lanes 1 and 4), GST-Ataxin-1[82Q] is able to pull down the
Drosophila and human Ataxin-2 proteins, which indicates that
both proteins are able to physically interact. We also asked
whether this interaction is polyglutamine dependent. As
shown in Figure 4B lanes 2–4 we did not detect signiﬁcant
differences in the interactions between GST-Ataxin-1 with 2,
30 or 82 glutamines and human Ataxin-2 in this co-AP assay.
Ataxin-1[82Q] is phosphorylated at Serine residue 776 on
the C-terminal portion of the protein, and a (Ser776Ala)
mutation inhibits the toxicity of Ataxin-1[82Q] in mice[17].
We investigated the importance of Ser776 for the Ataxin-
1[82Q]-dAtx2 interaction. As shown in (Figure 4A lane 3) the
interaction of dAtx2 with Ataxin-1[82Q]
S776A is weaker than
with normal Ataxin-1[82Q], suggesting that this interaction is
phosphorylation dependent.
In addition, we investigated if Ataxin-1 can pull down
endogenous hATX2. We ﬁnd that unexpanded Ataxin-1 is
able to precipitate endogenous hATX2 from human cells,
suggesting that the two proteins may be functional inter-
actors in vivo (Figure 4C).
We also investigated whether the interaction between
Ataxin-1 and Ataxin-2 is cytoplasmic or nuclear. We carried
out co-AP assays with Ataxin-1 and dAtx2 after nuclear/
cytoplasmic fractionation of cultured cells. Figure 4D shows
that we were not able to detect differences in protein
interactions between these cellular compartments using this
assay.
Lastly, we investigated whether speciﬁc domains of the
hAtaxin-1 protein are responsible for the interaction with
hAtaxin-2. Co-AP experiments were carried out with lysates
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Ataxin-1 and Ataxin-2 InteractionsFigure 3. dAtx2 Levels Modulate Ataxin-1[82Q]-Induced Loss of Mechanoreceptors
(A) Percentage of missing thoracic macrochaetae (large mechanoreceptor bristles) over a total of 26 in flies of the indicated genotypes raised at 258C.
Columns-1 and 2, no macrochaetae loss is detected in control flies or flies over-expressing dAtx2 (dAtx2
OE) in the thoracic sensory organ precursor (SOP)
cells respectively with the scabrous-GAL4 driver. Column-3, mild decrease in thoracic macrochaetae number caused by expression of Ataxin-1[82Q] at
low levels in the SOP cells (p,0.0001). Column-4, ;80% decrease in the number of thoracic macrochaetae in animals co-expressing Ataxin-1[82Q] and
dAtx2 (SCA1
82Q/dAtx2
OE) in the SOPs (p,0.0001). Error bars¼s.e.m.
(B–E) Images of the macrochaetae present in the posterior region of the notum and scutellum (white rectangle in B) of flies with same genotypes as (A).
(B) Control thoraxes have eight macrochaetae in the selected area (white rectangle). (C-E) Over-expression of dAtx2 enhances Ataxin-1[82Q] induced
macrochaetae loss. Black arrow indicates missing bristle in C and white arrow in E points to the only bristle present in the scutellum of an SCA1
82Q/
dAtx2
OE animal. Flies grown at 258C.
(F) Anti-Sens immunofluorescence revealing the normal pattern of Sens distribution in the wing disc. White rectangle highlights the wing margin SOP
and bristle precursor cells.
(G–J) Close-up of the wing margin region from: control animals (G), animals expressing Ataxin-1[82Q] alone (H), wild-type dAtx2 (I) or coexpressing
Ataxin-1[82Q] and dAtx2 (J).
(K) Quantification of anti-Sens signal in the wing margin of animals of the genotypes indicated on the bottom. 20 wing discs were used per genotype
and experiments carried out at 258C (see materials and methods for more details). Bars¼Std. Dev.
(L) Percentage of lost macrochaetae in flies expressing Ataxin-1[82Q] with normal or decreased levels of dAtx2. Flies grown at 278C to boost expression
levels of the GAL4/UAS system. Column-1, control animals do not show macrochaetae loss. Column-2, ;20% of thoracic macrochaetae are lost after
expression of Ataxin-1[82Q] at high levels in the SOP cells (p,0.0001). Column-3, partial rescue of Ataxin-1[82Q]-induced macrochaetae loss in animals
heterozygous for the dAtx2
X1 mutant (p,0.005). Bars¼ s.e.m. (M–N) Images of the macrochaetae present in the posterior notum and scutellum (white
rectangle in B) of flies with same genotypes as L. Arrows indicate missing bristles. Flies grown at 278C.
Genotypes: control: sca
109–68-GAL4/UAS-GFP. dAtx2
OE:sca
109–68-GAL4/ UAS- dAtx2 [4]. SCA1
82Q: UAS- SCA1
82Q [F7]/þ; sca
109–68-GAL4/þ. SCA1
82Q/dAtx2
OE:
UAS- SCA1
82Q [F7]/þ; sca
109–68-GAL4/ UAS- dAtx2 [4]. SCA1
82Q/dAtx2
X1: UAS-SCA1
82Q [F7]/þ; sca
109–68-GAL4/þ; dAtx2
X1/þ.
doi:10.1371/journal.pgen.0030234.g003
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Ataxin-1 and Ataxin-2 InteractionsFigure 4. The Ataxin-1[82Q] and Ataxin-2 Proteins Physically Interact
(A) GST Co-AP pull-down experiments between dAtx2 and GST-constructs carrying human Ataxin-1[82Q] or Ataxin-1[82Q] with S776A mutation.
(B) GST Co-AP experiments between human Ataxin-2 (Myc-hATXN2) and GST-Ataxin-1 with different polyglutamine lengths.
(C) Interaction between GST-Ataxin-1[2Q] and endogenous hATXN2 in cell culture.
(D) Co-AP pull down experiments between GST-Ataxin-1 and Flag-dAtx2 after nuclear/cytoplasmic fractionation. Tubulin is used as cytoplasmic marker
and Mecp2 as nuclear marker.
(E) Comparative analysis of the interaction of hAtaxin-2 with different domains of the Ataxin-1 protein. Lane-1, GST alone does not pull down Myc-
hAtaxin2. Lane-2, GST-ATXN1
82Q pulls down Myc-hAtaxin2. Lane-3 expanded N-terminal Ataxin-1 (GST-ATXN1N-term
82Q) lacking the AXH domain (aa#
1–575) also pulls down Myc-hAtaxin-2 with high affinity. Lanes-4 and 5 show that both the C-terminus portion of Ataxin-1 containing the AXH domain
(aa# 529–816; lane-4) or the AXH domain alone (aa# 558–700; lane-5) pull down Myc-hAtaxin2. These interactions are weaker than that of the N-
terminus part (compare lanes 4 and 5 with lane 3). Cell lysates for co-AP were ran through Glutathione conjugated beads, and blots stained with anti-
GST or anti-Myc. Immunoblots for dAtx2, Myc-hAtaxin2 and GFP carried out on cell lysates before the co-AP pull-down reveal similar levels of both
proteins between samples.
doi:10.1371/journal.pgen.0030234.g004
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Ataxin-1 and Ataxin-2 Interactionsfrom cells expressing Myc-hAtaxin-2 and one of the following
hAtaxin-1 fragments tagged with GST: polyglutamine ex-
panded N-terminal (aa# 1–575, Figure 4E lane-3), C-terminus
Ataxin-1 containing the AXH domain (aa# 529–816; Figure
4E lane-4) or the AXH domain alone (aa# 558–700; Figure 4E
lane-5). All three fragments pull-down Myc-hAtaxin-2, in-
dicating that each Ataxin-1 fragment can interact independ-
ently with hAtaxin-2 (Figure 4E lanes 3–5). However, the
interaction of hAtaxin-2 is stronger with the N-terminal
Ataxin-1 fragment (Figure 4E, lane-3) as compared to the C-
terminal or AXH portions (Figure 4E lanes 4 and 5
respectively), since less N-terminal peptide pulls down more
hAtaxin-2.
Ataxin-2 Accumulates in the Nucleus of Expanded Ataxin-
1-Expressing Drosophila Cells and Human Neurons
The co-AP assays with expanded hAtaxin-1 and hAtaxin-2
indicate that the two proteins are able to interact. However,
Ataxin-1 normally localizes to the nucleus in Drosophila and
many human cell types, while Ataxin-2 is a cytoplasmic
protein. To address whether the interaction observed in
cultured cells is relevant in vivo, we monitored the local-
ization of Ataxin-2 in Drosophila cells expressing Ataxin-
1[82Q]. Since Ataxin-1[82Q]-induced toxicity is suppressed
by dAtx2 loss of function in the Drosophila eye; we ﬁrst
analyzed the localization of dAtx2 in retinal cells. dAtx2 is not
normally detected in the nuclei of retinal cells from either
control eyes or eyes overexpressing dAtx2 (Figure 5A and C
respectively). In contrast, we ﬁnd that endogenous dAtx2
localizes to the nuclei of retinal cells expressing Ataxin-
1[82Q]. Furthermore, nuclear dAtx2 signal is detected both
diffusely in the nucleoplasm as well as in nuclear inclusions
(NIs) (Figure 5B). To conﬁrm this unexpected result, we
examined the localization of dAtx2 in other Ataxin-1[82Q]-
expressing neurons. Similar to the results obtained in the
retina, endogenous dAtx2 normally localizes to the cytoplasm
Figure 5. Expanded Ataxin-1 Induces Nuclear Accumulation of Ataxin-2 in Drosophila and Human Neurons
(A–C) Longitudinal paraffin sections through adult fly retinas stained with anti-dAtx2 antiserum (green). Nuclei are visualized with anti-Lamin (white).
Controls expressing only gmr-GAL4 driver (A) or gmr-GAL4 driver plus UAS-dAtx2 (C) show no detectable nuclear dAtx2 staining; arrowhead in (C) points
to cytoplasmic accumulation of dAtx2. (B) dAtx2 localizes to the nucleus and accumulates in NIs (arrows) in retinal cells of SCA1
82Q animals. Also notice
additional diffuse dAtx2 signal in the nuclei.
(D) Pattern of ok107-GAL4 in the VNC, showing the area we analyzed (white square).
(E–E99) Confocal images of control Drosophila neurons in the larval ventral ganglion expressing CD8:GFP from the ok107-GAL4 neuronal driver and
stained with anti-dAtx2 antibody. (E) No dAtx2 staining (red) is detected in the neuronal nucleus. Nuclear Lamin is shown in white. (E9) Same neurons as
E showing CD8:GFP to reveal the neuronal cytoplasm. Images are merged in E99.
(F–F99) Confocal images of ok107-GAL4 neurons expressing Ataxin-1[82Q] (SCA1
82Q) stained in parallel to E–E99. (F) Shows dAtx2 signal (red) inside the
nucleus (white) in the form of NIs (arrows), in addition to the cytoplasmic dAtx2 signal. (F9) Shows the same neurons visualized with CD8:GFP showing
neuronal cytoplasm (green). Images are merged in F99.
(G–G99) Triple immunofluorescence for Ubiquitin (blue), dAtx2 (red) and CD8:GFP (green) in ok107-GAL4 neurons expressing Ataxin-1[82Q]. Notice the
overlapping of the dAtx2 (G) and Ubiquitin (G9) signals in the merged image in G99 (arrows point to nuclear inclusions).
(H, I) Human pontine neurons stained with anti-human Ataxin-2 antibody (brown). Hematoxylin (blue) was used for counterstaining. (H) No staining is
detected in neuronal nuclei of non SCA1 postmortem tissue. (I) Ataxin-2 accumulates in NI (arrowhead) in a SCA1 neuron.
Genotypes: (A) gmr-GAL4/þ. (B) UAS-SCA1
82Q[F7]/þ; gmr-GAL4/þ. (C) gmr-GAL4/UAS-dAtx2[4]. (D, E-E99) UAS-CD8:GFP/þ;þ; ok107-GAL4/þ. (F-F99 and G-G99)
UAS-CD8:GFP/þ; UAS-SCA1
82Q [M6]/þ; ok107-GAL4/þ.
doi:10.1371/journal.pgen.0030234.g005
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Ataxin-1 and Ataxin-2 Interactionsand is not detected in the nuclei of neurons from the ventral
nerve cord (Figure 5 E-E99, ok107-GAL4 pattern shown in D).
However, Ataxin-1[82Q]-expressing VNC neurons show nu-
clear accumulation of dAtx2 (Figure 5 F-F99). Next we
investigated whether dAtx2 and Ataxin-1 colocalize. Co-
staining of Ataxin-1 and dAtx2 is not possible since the
available antibodies for both proteins were raised in rabbit;
however, Ataxin-1 NIs in Drosophila neurons are positive for
Ubiquitin [25], so we performed a double staining for dAtx2
and Ubiquitin. Figure 5G-G99 shows that the dAtx2 NIs
present in the neurons of SCA1
82Q ﬂies are positive for
Ubiquitin. These results indicate that expanded Ataxin-1
causes dAtx2 to localize to the nucleus and suggest that both
proteins co-aggregate in NIs.
To validate these results and investigate their relevance for
SCA1 pathogenesis, we analyzed the localization of hAtaxin-2
in SCA1 neurons from human postmortem brain samples by
anti-Ataxin-2 immunohistochemistry. Pontine neurons from
control samples consistently show cytoplasmic localization of
hAtaxin-2 (Figure 5H). Pontine neurons from SCA1 brain
samples display frequent Ataxin-1 NIs that are clearly visible
with Hematoxylin staining. We found that approximately
twenty percent of these NIs are positive for hAtaxin-2 (Figure
5I); see also[10]. These ﬁndings, together with the co-AP data
using human Ataxin-1 and Ataxin-2 proteins, suggest that the
Ataxin-1-Ataxin-2 interactions observed in Drosophila may be
relevant for SCA1 pathology.
Nuclear Accumulation of Ataxin-2 Is Induced by
Pathogenic Ataxin-1[82Q], but Not Unexpanded Ataxin-
1[2Q] and Ataxin-1[30Q]
SCA1 pathogenesis is triggered by polyglutamine expan-
sion in Ataxin-1 beyond 39–44 residues [5]. To investigate if
nuclear accumulation of Ataxin-2 is speciﬁc to the patho-
genic Ataxin-1 form, we analyzed dAtx2 localization in
Drosophila VNC neurons expressing human Ataxin-1 with
different polyglutamine lengths: Ataxin-1[2Q], Ataxin-1[30Q]
and Ataxin-1[82Q]. The Ataxin-1[2Q] line used has higher
levels of protein expression than the Ataxin-1[30Q] and [82Q]
lines, both of which have comparable expression levels
(Western blot data not shown). Figure 6A-D shows that no
nuclear dAtx2 signal is detected in control neurons (Figure
6A), or neurons expressing Ataxin-1[2Q] or [30Q] (Figure 6B
and C). In contrast, accumulation of dAtx2 is detected in the
nucleus of Ataxin-1[82Q]-expressing neurons (Figure 6D).
Although this result does not rule out an interaction between
wild-type Ataxin-1 and dAtx2, it indicates that abundant
nuclear accumulation of Ataxin-2 is speciﬁc to the expanded
Ataxin-1 form responsible for SCA1 pathogenesis.
Nuclear Accumulation of Ataxin-2 Causes Severe Eye
Toxicity
The observations that expanded Ataxin-1 induces nuclear
accumulation of Ataxin-2 and that decreasing the levels of
endogenous Ataxin-2 suppresses toxicity in SCA1
82Q ﬂies,
suggest that nuclear accumulation of Ataxin-2 may lead to
neurotoxicity. To test this hypothesis, we generated dAtx2
transgenic ﬂies with an exogenous nuclear localization signal
(NLS) engineered on its C-terminus end (dAtx2
NLS) (Figure 7
compare A-A9 with C). Although wild-type Ataxin-2 is only
detected in the cytoplasm in Drosophila and human neurons, it
is difﬁcult to rule out the possibility that some Ataxin-2 may
be present in the nucleus. Therefore, we also generated ﬂies
carrying a dAtx2 construct with an exogenous nuclear export
signal (NES) (dAtx2
NES) to use as an additional control (Figure
7B-B9). Ten transgenic lines were recovered for each dAtx2
construct, with a wide range of expression levels for each
transgene. We selected transgenic lines expressing wild-type
dAtx2 (dAtx2
OE), dAtx2
NES or dAtx2
NLS at similar levels
(Figure 7D compare lanes 2–4), and compared their toxicity
in the eye. As shown in Figure 7E-H, dAtx2
NLS is more toxic
than wild-type dAtx2 or dAtx2
NES. While both wild-type
dAtx2 and dAtx2
NES induce a relatively mild eye phenotype
compared to controls (Figure 7 E-G), expression of dAtx2
NLS
results in strong eye toxicity (Figure 7H). Eyes of dAtx2
NLS
ﬂies show a severely disorganized ommatidial lattice and a
Figure 6. Pathogenic Ataxin-1[82Q], but Not Unexpanded Ataxin-1, Induces Nuclear Accumulation of dAtx2 In Vivo
(A–D) Anti-dAtx2 immunofluorescence (red) in ventral ganglion neurons expressing different Ataxin-1 transgenes and CD8-GFP (green) with the ok107-
GAL4 driver. Nuclear Lamin (white) is also shown. (A) Control neurons show no nuclear dAtx2. (B) Neurons expressing Ataxin-1 with only 2Q (SCA1
2Q)
present no nuclear dAtx2. (C) Neurons expressing wild type human Ataxin-1 with 30Q (SCA1
30Q) fail to show nuclear dAtx2 as well. (D) Neurons
expressing expanded Ataxin-1[82Q] (SCA182Q) present nuclear dAtx2.
Genotypes: (A) UAS-CD8:GFP/þ;þ; ok107-GAL4/þ. (B) UAS-CD8:GFP/þ; UAS-SCA1
2Q [F14]/þ; ok107-GAL4/þ(C) UAS-SCA1
30Q [F1]/yw; UAS-CD8:GFP/þ; ok107-
GAL4/þ. (D) UAS-CD8:GFP/þ; UAS-SCA1
82Q [M6]/þ; ok107-GAL4/þ.
doi:10.1371/journal.pgen.0030234.g006
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Ataxin-1 and Ataxin-2 Interactionscomplete absence of interommatidial bristles (Figure 7H).
These observations were consistent in several lines for each of
the dAtx2 constructs at similar levels of expression (data not
shown).
In summary, expression of dAtx2
NES and wild-type dAtx2
in the eye cause similar mild phenotypes. This is consistent
with dAtx2 being mainly cytoplasmic, and with observations
of SCA2 pathogenesis in the cytoplasm[44,45]. Interestingly,
increasing the levels of Ataxin-2 in the nucleus is sufﬁcient to
cause a much more severe eye phenotype. These observations
suggest that the toxicity of expanded Ataxin-1 is mediated in
part, by the nuclear accumulation of Ataxin-2.
Nuclear Ataxin-2 Decreases Sens Protein Levels and
Induces Loss of Mechanoreceptor Bristles
To further test the hypothesis that nuclear Ataxin-2
contributes to expanded Ataxin-1-induced toxicity, we
analyzed the effect of expressing the different dAtx2 trans-
genes on Sens distribution in the wing margin SOPs.
Expression of Ataxin-1[82Q] in the antero-posterior com-
partment boundary (using dpp-GAL4) induces a cell autono-
mous decrease of Sens only in the dpp-GAL4 expressing area
of the wing margin (Figure 8A, A9 and 8B, B9, arrowhead).
This provides a molecular readout of Ataxin-1[82Q]-induced
neurotoxicity.
Expression of dAtx2
NES from dpp-GAL4 does not reduce the
levels of Sens, whose distribution in imaginal wing discs is
unchanged (Figure 8C and C9, arrowhead). Next, we tested the
effect of dAtx2 with a nuclear localization signal (dAtx2
NLS).
Like Ataxin-1[82Q], expression of dAtx2
NLS induces loss of
Sens in the wing margin SOPs (Figure 8D and D9, arrowhead).
dAtx2
NLS-induced loss of Sens is also observed in other cell
types. Salivary gland cells express Sens at high levels [20],
which localizes to the nucleus (Figure 8E-H). Salivary gland
cells expressing dAtx2
NES show no detectable change in Sens
levels or distribution (Figure 8I-L). In contrast, expression of
dAtx2
NLS causes a dramatic decrease in the amount of Sens
(Figure 8M-P). The nuclei of dAtx2
NLS cells are still present
and their morphology is similar to controls, indicating that
Sens loss is unlikely a consequence of cell death. Therefore,
nuclear dAtx2 mimics Ataxin-1[82Q] in causing loss of Sens
protein accumulation.
Expression of Ataxin-1 in the thoracic SOPs (using sca-
GAL4) leads to loss of macrochaetae in the adult thorax
(Figure 3 and ref.[18]). Therefore, we also investigated the
consequences of nuclear or cytoplasmic Ataxin-2 accumu-
Figure 7. Nuclear Accumulation of dAtx2 Increases Its Toxicity In Vivo
(A–C) Immunofluorescence staining to reveal the localization of dAtx2 in neurons overexpressing CD8:GFP together with wild-type dAtx2 (dAtx2
OE)o r
dAtx2 with a nuclear export or a nuclear localization signal (dAtx2
NES or dAtx2
NLS, respectively). (A and A9) dAtx2 localizes to the cytoplasm even when
overexpressed. (B and B9) dAtx2
NES distribution is similar to that of wild-type dAtx2. (C) nuclear localization of dAtx2
NLS.
(D) Anti-dAtx2 immunoblot demonstrating similar expression levels of the different dAtx2 transgenes used in this work. The transgenes were driven by
gmr-GAL4. Larval eye imaginal discs (ten per genotype) were used to avoid artifact potentially caused by cell degeneration or loss. dTubulin was blotted
for loading control and larvae cultured at 258C. Relative protein expression levels are indicated below normalized to the wild-type dAtx2 overexpressing
line (dAtx2
OE, underlined)
(E–H) SEM images showing the eye phenotypes caused by the different dAtx2 transgenes at 258C. Transgenes were expressed with gmr-GAL4. (E)
Control eyes. (F) Wild-type dAtx2 over-expression (dAtx2
OE) in the eye causes a mild phenotype with some ommatidial disorganization and bristle loss.
(G) Expression of dAtx2
NES causes a similar phenotype to that caused by wild-type dAtx2. (H) Expression of dAtx2
NLS at similar levels as wild-type dAtx2
causes severe eye degeneration; the structure of the ommatidia is lost and interommatidial bristles are absent. In addition there is a strong decreasei n
eye size.
Genotypes: (A, A9) UAS-CD8-GFP/UAS-dAtx2[4]; ok107-GAL4/þ. (B, B9) UAS-CD8-GFP/þ; UAS-dAtx2
NES/þ; ok107-GAL4/þ. (C) UAS-CD8-GFP/UAS-dAtx2
NLS;
ok107-GAL4/þ. (D–H) Control: gmr-GAL4/UAS-GFP. dAtx2
OE: gmr-GAL4/UAS-dAtx2[4]. dAtx2
NLS: gmr-GAL4/ UAS-dAtx2
NLS. dAtx2
NES: gmr-GAL4/þ; UAS-
dAtx2
NES /þ.
doi:10.1371/journal.pgen.0030234.g007
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Ataxin-1 and Ataxin-2 InteractionsFigure 8. Nuclear dAtx2 Induces Decreased Levels of Senseless (Sens) Protein and Loss of Mechanoreceptors
(A–D9) Immunofluorescence staining revealing Sens endogenous pattern in the wing margin SOPs on animals of genotypes indicated on top. (A and A9)
Distribution of Sens in wing discs expressing a neutral NLS-DsRed protein (RedStinger) in the dpp territory (red in A9). Sens is detected as two parallel
rows of cells (SOPs of the dorsal and ventral wing margins) uninterrupted in the area where they cross the dpp territory (arrowhead). (B, B9) Ataxin-
1[82Q] eliminates Sens signal in the wing discs in a cell autonomous manner. Notice the gap in Sens signal when it crosses the dpp territory (arrowhead)
expressing Ataxin-1[82Q] (red in B9). (C, C9) Expression of dAtx2
NES (red in C9) in the dpp territory does not affect Sens signal (arrowhead). (D, D9)
Expression of dAtx2
NLS (red in D9) in the dpp territory reduces Sens signal in the SOPs, note the gap in Sens pattern (arrowhead).
(E–P) Immunofluorescence staining revealing Sens (red, anti-Sens) and the dAtx2
NES or dAtx2
NLS proteins (green, anti-Flag), in salivary gland cells of the
indicated genotypes. Nuclei are visualized using anti-Lamin (blue). (E–H) Control salivary gland cells showing robust Sens signal. Asterisks in G indicate
the position of the nuclei. (I–L) dAtx2
NES-expressing salivary gland cells have normal Sens levels when compared to controls. (M–P) Expression of
dAtx2
NLS in salivary gland cells causes a decrease of Sens protein. Sens signal (red) is dramatically decreased in dAtx2
NLS-expressing cells (compare N
with F and J). Asterisks in N indicate the position of the nuclei.
(Q–S) Effect of dAtx2
NES or dAtx2
NLS on adult thoracic macrochaetae formation after SOP specific expression. (Q) SOP-specific expression of dAtx2
NES
causes no macrochaetae loss. (R) Expression of dAtx2
NLS in the SOP cells causes significant macrochaetae loss in the same conditions as Q. Arrows point
out missing macrochaetae. (S) Quantification of lost macrochaetae in adult thoraxes of the same genotypes as Q and R. Column-1 shows no decrease in
the number of macrochaetae per thorax in flies expressing dAtx2
NES. Column-2 reveals increased loss of macrochaetae following SOP specific
expression of Atx2
NLS (p,0.0001). 20 animals were used per genotype; data was analyzed using Students t; error bars represent s.e.m. Experiments in
Q–S were performed at 258C.
Genotypes: (A, A9) dpp-GAL4/ UAS-RedStinger. (B, B9) UAS-SCA1
82Q[F7]/þ;þ;dpp-GAL4/þ. (C, C9, I–L) dpp-GAL4/UAS-dAtx2
NES. (D, D9, M–P) UAS-dAtx2
NLS /þ;
dpp-GAL4/þ (E–H) dpp-GAL4/þ. (Q–S) dAtx2
NES: sca
109–68-GAL4/þ; UAS-dAtx2
NES /þ. dAtx2
NLS: sca
109–68-GAL4/ UAS-dAtx2
NLS.
doi:10.1371/journal.pgen.0030234.g008
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Ataxin-1 and Ataxin-2 Interactionslation on the development of adult macrochaetae. As with
wild-type dAtx2 (Figure 3), expression of dAtx2
NES in the
thoracic SOP cells causes no visible change in the number of
macrochaetae in the adult thorax (Figure 8Q and Figure 8S
column-1). In contrast, expression of dAtx2
NLS induces a
signiﬁcant decrease in the number of macrochaetae, with an
approximate twenty percent reduction in comparison to
control animals (Figure 8R and Figure 8S column-2). These
results indicate that increasing the levels of nuclear dAtx2
mimics expanded Ataxin-1 in inducing loss of mechanor-
eceptors and reducing the levels of Sens protein.
Discussion
Here we report functional interactions between the
proteins causing two distinct Spinocerebellar ataxias. We
use a Drosophila model of SCA1 to show that wild-type dAtx2
(the ﬂy homolog of the protein that when expanded causes
SCA2) mediates, at least in part, neuronal degeneration
caused by expanded Ataxin-1 (the protein triggering SCA1).
Ataxin-1[82Q]-induced toxicity is worsened by increasing the
levels of dAtx2. More signiﬁcantly, decreasing the levels of
dAtx2 suppresses expanded Ataxin-1-induced neuronal de-
generation as shown in several independent assays. The
suppression of Ataxin-1[82Q] phenotypes by partial loss of
function of dAtx2 argues against a possible mechanism by
which sequestration and depletion of Ataxin-2 contributes to
expanded Ataxin-1-induced neurodegeneration. This is fur-
ther supported by lack of cerebellar or other neuronal
abnormalities in mice that are deﬁcient for Ataxin-2[46].
We ﬁnd that the human expanded Ataxin-1 interacts with
the dAtx2 and human Ataxin-2 proteins in co-AP assays.
Furthermore, overexpressed Ataxin-1 pulls down endogenous
hAtaxin-2 in cultured cells. These results suggest that Ataxin-
1 and Ataxin-2 may be functional interactors in vivo.
Consistent with this, we ﬁnd that expanded Ataxin-1 induces
accumulation of Ataxin-2 in the nucleus, where the two
proteins localize in NIs both in Drosophila neurons and SCA1
human brain tissue. These are surprising observations since
Ataxin-2 is normally a cytoplasmic protein both in humans
and Drosophila. Interestingly, wild-type Ataxin-1 can cause
neurotoxicity when overexpressed, although to a much lesser
extent than expanded Ataxin-1 [25]. However, nuclear
accumulation of dAtx2 is triggered by pathogenic but not
wild-type forms of Ataxin-1, at least in detectable amounts.
Taken together these data suggested that accumulation of
Ataxin-2 in the nucleus contributes to the exacerbated
toxicity of expanded Ataxin-1, and is an important mecha-
nism of pathogenesis in SCA1. To investigate this hypothesis
we targeted dAtx2 to the nucleus by means of an exogenous
NLS signal. We ﬁnd that dAtx2
NLS is sufﬁcient to cause a
dramatic increase of its toxicity, when compared to either
wild-type dAtx2 or dAtx2 with an exogenous nuclear export
signal (dAtx2
NES) expressed at similar levels.
To further test the hypothesis that nuclear accumulation of
Ataxin-2 contributes to neurodegeneration caused by ex-
panded Ataxin-1 we investigated Sens levels. Sens and its
murine orthologue Gﬁ1 are proneural factors whose levels
are decreased in the presence of expanded Ataxin-1[18]; thus
providing a molecular readout for the neurotoxicity of
Ataxin-1. In Drosophila, reduction of Sens levels leads to the
loss of mechanoreceptors [18], so we monitored Sens in the
context of ﬂies expressing either dAtx2
NLS or dAtx2
NES but
not carrying the Ataxin-1[82Q] transgene. We ﬁnd that
nuclear targeted, but not cytoplasmic, dAtx2 mimics both
the Sens reduction and mechanoreceptor loss phenotypes
caused by Ataxin-1[82Q].
Expanded Ataxin-2 accumulates both in the cytoplasm and
the nuclei of SCA2 postmortem brains [2,47–49]. In mouse
and cell culture models of SCA2, expanded Ataxin-2
accumulates in the cytoplasm and its nuclear accumulation
is not necessary to induce toxicity [44,45]. However, nuclear
accumulation of expanded Ataxin-2 also occurs in cultured
cells [45], and is consistently observed in human SCA2
postmortem brainstem neurons [2,47–49]. These observations
suggest that both nuclear and cytoplasmic mechanisms of
pathogenesis contribute to neurodegeneration in SCA2, as it
is known to occur in other polyglutamine diseases like HD
and SCA3 [50–52]. One possibility is that Ataxin-2 shuttles
between the nucleus and the cytoplasm although the protein
is normally detected only in the cytoplasm. Our data show
that accumulation of dAtx2 in the nucleus is more harmful
than in the cytoplasm. Thus, neurons with nuclear Ataxin-2 in
SCA2 patients may be relatively more compromised than
neurons where Ataxin-2 accumulates in the cytoplasm. In
agreement with this possibility, expanded Ataxin-2 is found
in the nuclei of pontine neurons of SCA2 brains, one of the
neuronal groups and brain regions with prominent degener-
ation in SCA2 [2,47–49].
Reducing Ataxin-2 levels suppresses expanded Ataxin-1
toxicity, strongly arguing against a mechanism of patho-
genesis by loss of function of Ataxin-2 in the cytoplasm.
Studies of the normal function of Ataxin-2 and its yeast
[29,30], C. elegans [31], and Drosophila [32,33] homologs suggest
a role in translational regulation. Thus, an attractive
possibility is that Ataxin-1 [82Q] requires dAtx2 to impair
Sens translation and induce the loss of mechanoreceptors.
Consistent with this hypothesis is the ﬁnding that partial loss
of function of dAtx2 suppresses the loss of mechanoreceptors
phenotype caused by expanded Ataxin-1.
The data described here uncover unexpected functional
interactions between proteins involved in two different SCAs.
Nuclear accumulation of Ataxin-2, normally a cytoplasmic
protein, is a common denominator of SCA1 and SCA2, and
leads to reduced levels of at least one important proneural
factor; i.e. Sens, whose mammalian orthologue Gﬁ1 is
required for Purkinje cell survival [18]. Thus neuronal
degeneration may take place through common mechanisms
in different ataxias, and one of these mechanisms may involve
the abnormal accumulation of Ataxin-2 in neuronal nuclei.
Methods
Drosophila strains. The cDNA GH27029 containing dAtx2 was
obtained from the BDGP repository. SV40 nuclear localization signal
and PKI nuclear export signal were engineered on the 39 end of dAtx2
cDNA by PCR. Both constructs were then subcloned ﬁrst in pGEM
t-T
(Promega) and then in a previously generated pUAST-ﬂag expression
vector[53,54]. The Drosophila transgenic lines UAS-dAtx2
NES and UAS-
dAtx2
NLS were obtained by injecting both constructs following
standard procedures. EP(3)3145 was obtained from the Szeged
Drosophila Stock Center in Hungary. The wild type UAS-dAtx2
(dAtx2OE) and mutant dAtx2-X1 lines [33] were kindly provided by
Dr. Pallanck, L.J.. The UAS-SCA182Q, UAS-SCA130Q and UAS-
SCA12Q lines have been previously described [7,25]. N-Htt128Q ﬂies
have been previously described [7,43]. All other Drosophila strains
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Indiana University.
Scanning electron microscopy and retinal parafﬁn sections. We
used previously published procedures [7,25].
Scoring of macrochaetae in adult thoraxes. Flies were raised at
either 258C for low Ataxin-1[82Q] expression levels or 278C for high
Ataxin-1[82Q] expression levels. Flies were collected at day 1 and the
number of macrochaetae per thorax of same sex ﬂies was counted for
20 animals per genotype. The percentage of lost macrochaetae over a
total of 26 was calculated, and the average per genotype was plotted
in the chart.
Motor performance assay. Between 25 and 30 adult females per
genotype are collected for periods no longer than 24 hours. Flies are
transferred to vials containing new food every day. The assay is
carried out in an empty vial. The vial is tapped so all ﬂies fall to the
bottom then we score ﬂies that climb past a line 5cm high in 18
seconds, and this procedure is repeated ten times for each day shown
in the chart. The average percentage of ﬂies climbing per day is then
calculated and plotted in Microsoft Excel. Experiments are always
performed at the same time in the day to ensure no circadian rhythm
effects. Four replicas (25,n,30) are analyzed per genotype. Motor
performance in each replica is measured until all animals failed to
reach the 5 cm line.
Protein–protein interaction assay. Gst co-afﬁnity puriﬁcation
assays between GST-ATXN1
2Q, GST-ATXN1
30Q, GST-ATXN1
82Q,
GST-ATXN1N-term
82Q, GST-ATXN1C-term GST-ATXN1-AXH or
GST-ATXN1
82QS776A, and dAtx2, Flag-dAtx2 or Myc-hAtaxin-2 were
carried out as previously published [55]. pEGFP-C1 vector was used
for control and constructs were transfected in HEK293T cells.
Immunoblots were carried out following standard procedures and
stained with mouse anti-Myc (9E10) and rabbit anti-GST antibodies
(Sigma).
Immunoﬂuorescence staining. Tissues were dissected and ﬁxed in
4% formaldehyde. Following standard procedures tissues were
incubated with rabbit anti-dAtx2 (1:2000, courtesy of Leo J. Pallanck),
Lc2628 anti-nuclear Lamin (1:50, Hybridoma Bank), rabbit anti-ﬂag
(1:200, Sigma), 11NQ rabbit anti-Ataxin-1 (1:750), 6C1 mouse anti-
Ubiquitin (Sigma), guinea pig anti-Sens (1:1000, Hugo Bellen).
Secondary antibodies were obtained from Jackson Labs and
Molecular Probes. The ﬂuorescent images were documented in a
LSM510 Zeiss confocal microscope.
Quantiﬁcation of Sens signal. Sens quantiﬁcation in the SOP and
bristle precursor cells of the wing margins was carried as follows:
animals were raised at 258C. immunoﬂuorescence was done on wing
discs of the different genotypes (gp anti-Sens 1:1000, Hugo Bellen).
Confocal images were obtained throughout the thickness of the wing
margin (20 sections per wing disc with 2 lm interval) and then the
signal was stacked and summed. Quantiﬁcation was carried out by
selecting the area covered by each wing margin (dorsal or ventral)
separately and calculating ﬂuorescence and area. Data corresponding
to 20 wing discs per genotype was analyzed by Tukey-Kramer HSD
and plotted in a chart.
Immunohistochemistry on human post-mortem brain tissue.
Materials were stained as previously described [7].
dAtx2 immunoblotting. Eye imaginal discs from ten larvae per
genotype were dissected in cold PBS, homogenized in 30 llo f
Laemmli buffer (Bio-Rad) using a pellet pestle motor (Kontes) and
loaded on a 7.5% Tris-HCl Ready Gel (Bio-Rad). Membranes were
stained with primary antibodies rabbit anti-dAtx2 (1:5000, L.J.
Pallanck) and mouse anti-tubulin (Hybridoma Bank, 1:1000). Horse-
radish peroxidase-conjugated anti-mouse or anti-rabbit IgG secon-
dary antibodies (1:5000; Bio-Rad) were used and membranes were
developed using ECL Western blot detection kit (Amersham
Biosciences).
Supporting Information
Figure S1. Co-Expression of dAtx2 Reverts the Suppression of
Ataxin-1 [82Q]-Induced Degeneration Observed in SCA1
82Q/dAtx2
X1
Animals
(A-D9) SEM images of eyes from ﬂies of the genotypes indicated on
top. (A, A9) normal shape and arrangement of ommatidia in control
animals (w; gmr-GAL4/UAS-GFP; þ). (B, B9) Ataxin-1 [82Q] expression
causes distortionof ommatidia and loss of inter-ommatidial bristles in
SCA1
82Q animals (UAS-SCA1
82Q/þ; gmr-GAL4/þ). (C, C9) Suppression of
the phenotype induced by Ataxin-1 [82Q] in ﬂies with only one
functional copy of dAtx2 (UAS-SCA182Q/þ; gmr-GAL4/þ; dAtx2
X1/þ).
Note in C9 improved arrangement of ommatidia, and more
interommatidial bristles. (D, D9) Expression of low levels of dAtx2 in
Ataxin-1 [82Q] ﬂies that are also heterozygous for the dAtx2
X1 allele
(UAS-SCA1
82Q/þ; gmr-GAL4/UAS-dAtx2[B]; dAtx2
X1/þ) reverts the sup-
pression observed in SCA1
82Q/dAtx2
X1ﬂies. Note that the eye pheno-
type observed in D and D9 is more similar to B and B9 than to C and C9
both at the level of ommatidial disorganization, as well as bristle loss.
Found at doi:10.1371/journal.pgen.0030234.sg001 (5.7 MB TIF).
Figure S2. Levels of dAtx2 Protein in Control and Mutant Flies
Carrying the Alleles Used in This Work
(A) Comparison between dAtx2 in wild-type and homozygous mutant
dAtx2
X1/dAtx2
X1 ovaries. Note the absence of dAtx2 signal in dAtx2
X1/
dAtx2
X1 ovaries.
(B) Increased levels of dAtx2 are observed when dAtx2 is overex-
pressed in the eye with the dAtx2
OE line, in comparison with the levels
observed in wild-type ﬂies.
Genotypes: (A) Control: yw. dAtx2
X1/X1:HS-Flp/þ; FRT, dAtx2
X1/ FRT,
dAtx2
X1. (B) Control: w; gmr-GAL4/þ; þ. dAtx2
OE: w; gmr-GAL4/UAS-
dAtx2;þ.
Found at doi:10.1371/journal.pgen.0030234.sg002 (3.3 MB TIF).
Accession Numbers
NCBI protein accession data: NP_002964, NP_732034, NP_650466,
NP_732033, NP_524818, NP_002102, NP_000323; OMIM disease
reference: #164400, #183090.
Acknowledgments
We thank the Bloomington and Szeged Drosophila Stock Centers for
ﬂy strains, the Developmental Studies Hybridoma Bank for mono-
clonal antibodies, B. Antalfy and the MRDDRC cores (HD24062) for
sectioning and staining the human material, J. Barrish for help with
SEM, R. Atkinson for help with confocal microscopy, L. J. Pallanck for
the wild type UAS:dAtx2 and the dAtx2
X1 mutant Drosophila lines and
anti-dAtx2 antibody, H. J. Bellen for anti-Sens antibody, L. Koehler
for technical assistance, and H. Jafar-Nejad and the members of the
Botas laboratory for helpful discussion.
Author contributions. I. Al-Ramahi, J. Lim, S. M. Pulst, H. Y.
Zoghbi, and J. Botas conceived and designed the experiments. I. Al-
Ramahi, A. M. Pe ´rez, J. Lim, M. Zhang, R. Sorensen, and J. Branco
performed the experiments. I. Al-Ramahi, A. M. Pe ´rez, J. Lim, S. M.
Pulst, H. Y. Zoghbi, and J. Botas analyzed the data. M. de Haro, S. M.
Pulst, and H. Y. Zoghbi contributed reagents/materials/analysis tools.
I. Al-Ramahi and J. Botas wrote the paper.
Funding. This work was supported by a grant from the National
Institutes of Health to J. Botas (NS42179). HYZ is a Howard Hughes
Medical Institute investigator.
Competing interests. The authors have declared that no competing
interests exist.
References
1. Taroni F, DiDonato S (2004) Pathways to motor incoordination: the
inherited ataxias. Nat Rev Neurosci 5: 641–655.
2. Koeppen AH (2005) The pathogenesis of spinocerebellar ataxia. Cerebel-
lum 4: 62–73.
3. Soong BW, Paulson HL (2007) Spinocerebellar ataxias: an update. Curr
Opin Neurol 20: 438–446.
4. Lim J, Hao T, Shaw C, Patel AJ, Szabo G, et al. (2006) A protein-protein
interaction network for human inherited ataxias and disorders of Purkinje
cell degeneration. Cell 125: 801–814.
5. Orr HT, Zoghbi HY (2001) SCA1 molecular genetics: a history of a 13 year
collaboration against glutamines. Hum Mol Genet 10: 2307–2311.
6. Okazawa H, Rich T, Chang A, Lin X, Waragai M, et al. (2002) Interaction
between mutant ataxin-1 and PQBP-1 affects transcription and cell death.
Neuron 34: 701–713.
7. Al-Ramahi I, Lam YC, Chen HK, de Gouyon B, Zhang M, et al. (2006) CHIP
protects from the neurotoxicity of expanded and wild-type ataxin-1 and
promotes their ubiquitination and degradation. J Biol Chem 281: 26714–
26724.
8. Cummings CJ, Mancini MA, Antalffy B, DeFranco DB, Orr HT, et al. (1998)
Chaperone suppression of aggregation and altered subcellular proteasome
localization imply protein misfolding in SCA1. Nat Genet 19: 148–154.
9. Tsai CC, Kao HY, Mitzutani A, Banayo E, Rajan H, et al. (2004) Ataxin 1, a
SCA1 neurodegenerative disorder protein, is functionally linked to the
silencing mediator of retinoid and thyroid hormone receptors. Proc Natl
Acad Sci U S A 101: 4047–4052.
PLoS Genetics | www.plosgenetics.org December 2007 | Volume 3 | Issue 12 | e234 2563
Ataxin-1 and Ataxin-2 Interactions10. Uchihara T, Fujigasaki H, Koyano S, Nakamura A, Yagishita S, et al. (2001)
Non-expanded polyglutamine proteins in intranuclear inclusions of
hereditary ataxias–triple-labeling immunoﬂuorescence study. Acta Neuro-
pathol (Berl) 102: 149–152.
11. Warrick JM, Morabito LM, Bilen J, Gordesky-Gold B, Faust LZ, et al. (2005)
Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a
ubiquitin-associated mechanism. Mol Cell 18: 37–48.
12. Orr HT, Zoghbi HY (2007) Trinucleotide repeat disorders. Annu Rev
Neurosci 30: 575–621.
13. Riley BE, Orr HT (2006) Polyglutamine neurodegenerative diseases and
regulation of transcription: assembling the puzzle. Genes Dev 20: 2183–
2192.
14. Duenas AM, Goold R, Giunti P (2006) Molecular pathogenesis of
spinocerebellar ataxias. Brain 129: 1357–1370.
15. Gatchel JR, Zoghbi HY (2005) Diseases of unstable repeat expansion:
mechanisms and common principles. Nat Rev Genet 6: 743–755.
16. Klement IA, Skinner PJ, Kaytor MD, Yi H, Hersch SM, et al. (1998) Ataxin-1
nuclear localization and aggregation: role in polyglutamine-induced
disease in SCA1 transgenic mice. Cell 95: 41–53.
17. Emamian ES, Kaytor MD, Duvick LA, Zu T, Tousey SK, et al. (2003) Serine
776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1
transgenic mice. Neuron 38: 375–387.
18. Tsuda H, Jafar-Nejad H, Patel AJ, Sun Y, Chen HK, et al. (2005) The AXH
domain of Ataxin-1 mediates neurodegeneration through its interaction
with Gﬁ-1/Senseless proteins. Cell 122: 633–644.
19. Mizutani A, Wang L, Rajan H, Vig PJ, Alaynick WA, et al. (2005) Boat, an
AXH domain protein, suppresses the cytotoxicity of mutant ataxin-1. Embo
J 24: 3339–3351.
20. Nolo R, Abbott LA, Bellen HJ (2000) Senseless, a Zn ﬁnger transcription
factor, is necessary and sufﬁcient for sensory organ development in
Drosophila. Cell 102: 349–362.
21. Li SH, Li XJ (2004) Huntingtin-protein interactions and the pathogenesis
of Huntington’s disease. Trends Genet 20: 146–154.
22. Bilen J, Bonini NM (2005) Drosophila as a model for human neuro-
degenerative disease. Annu Rev Genet 39: 153–171.
23. Zoghbi HY, Botas J (2002) Mouse and ﬂy models of neurodegeneration.
Trends Genet 18: 463–471.
24. Marsh JL, Thompson LM (2006) Drosophila in the study of neuro-
degenerative disease. Neuron 52: 169–178.
25. Fernandez-Funez P, Nino-Rosales ML, de Gouyon B, She WC, Luchak JM, et
al. (2000) Identiﬁcation of genes that modify ataxin-1-induced neuro-
degeneration. Nature 408: 101–106.
26. Nonhoff U, Ralser M, Welzel F, Piccini I, Balzereit D, et al. (2007) Ataxin-2
interacts with the DEAD/H-box RNA helicase DDX6 and interferes with P-
bodies and stress granules. Mol Biol Cell 18: 1385–1396.
27. He W, Parker R (2000) Functions of Lsm proteins in mRNA degradation
and splicing. Curr Opin Cell Biol 12: 346–350.
28. Ralser M, Albrecht M, Nonhoff U, Lengauer T, Lehrach H, et al. (2005) An
integrative approach to gain insights into the cellular function of human
ataxin-2. J Mol Biol 346: 203–214.
29. Dunn CD, Jensen RE (2003) Suppression of a defect in mitochondrial
protein import identiﬁes cytosolic proteins required for viability of yeast
cells lacking mitochondrial DNA. Genetics 165: 35–45.
30. Mangus DA, Amrani N, Jacobson A (1998) Pbp1p, a factor interacting with
Saccharomyces cerevisiae poly(A)-binding protein, regulates polyadenyla-
tion. Mol Cell Biol 18: 7383–7396.
31. Ciosk R, DePalma M, Priess JR (2004) ATX-2, the C. elegans ortholog of
ataxin 2, functions in translational regulation in the germline. Develop-
ment 131: 4831–4841.
32. Satterﬁeld TF, Pallanck LJ (2006) Ataxin-2 and its Drosophila homolog,
ATX2, physically assemble with polyribosomes. Hum Mol Genet 15: 2523–
2532.
33. Satterﬁeld TF, Jackson SM, Pallanck LJ (2002) A Drosophila homolog of the
polyglutamine disease gene SCA2 is a dosage-sensitive regulator of actin
ﬁlament formation. Genetics 162: 1687–1702.
34. Pulst SM, Nechiporuk A, Nechiporuk T, Gispert S, Chen XN, et al. (1996)
Moderate expansion of a normally biallelic trinucleotide repeat in
spinocerebellar ataxia type 2. Nat Genet 14: 269–276.
35. Sanpei K, Takano H, Igarashi S, Sato T, Oyake M, et al. (1996) Identiﬁcation
of the spinocerebellar ataxia type 2 gene using a direct identiﬁcation of
repeat expansion and cloning technique, DIRECT. Nat Genet 14: 277–284.
36. Imbert G, Saudou F, Yvert G, Devys D, Trottier Y, et al. (1996) Cloning of
the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to
expanded CAG/glutamine repeats. Nat Genet 14: 285–291.
37. Rorth P, Szabo K, Bailey A, Laverty T, Rehm J, et al. (1998) Systematic gain-
of-function genetics in Drosophila. Development 125: 1049–1057.
38. Ghosh S, Feany MB (2004) Comparison of pathways controlling toxicity in
the eye and brain in Drosophila models of human neurodegenerative
diseases. Hum Mol Genet 13: 2011–2018.
39. Shulman JM, Feany MB (2003) Genetic modiﬁers of tauopathy in
Drosophila. Genetics 165: 1233–1242.
40. Ganetzky B, Flanagan JR (1978) On the relationship between senescence
and age-related changes in two wild-type strains of Drosophila mela-
nogaster. Exp Gerontol 13: 189–196.
41. Feany MB, Bender WW (2000) A Drosophila model of Parkinson’s disease.
Nature 404: 394–398.
42. Iijima K, Liu HP, Chiang AS, Hearn SA, Konsolaki M, et al. (2004)
Dissecting the pathological effects of human Abeta40 and Abeta42 in
Drosophila: a potential model for Alzheimer’s disease. Proc Natl Acad Sci U
S A 101: 6623–6628.
43. Kaltenbach LS, Romero E, Becklin RR, Chettier R, Bell R, et al. (2007)
Huntingtin interacting proteins are genetic modiﬁers of neurodegenera-
tion. PLoS Genet 3: e82. doi:10.1371/journal.pgen.0030082
44. Huynh DP, Figueroa K, Hoang N, Pulst SM (2000) Nuclear localization or
inclusion body formation of ataxin-2 are not necessary for SCA2 patho-
genesis in mouse or human. Nat Genet 26: 44–50.
45. Huynh DP, Yang HT, Vakharia H, Nguyen D, Pulst SM (2003) Expansion of
the polyQ repeat in ataxin-2 alters its Golgi localization, disrupts the Golgi
complex and causes cell death. Hum Mol Genet 12: 1485–1496.
46. Kiehl TR, Nechiporuk A, Figueroa KP, Keating MT, Huynh DP, et al. (2006)
Generation and characterization of Sca2 (ataxin-2) knockout mice.
Biochem Biophys Res Commun 339: 17–24.
47. Koyano S, Uchihara T, Fujigasaki H, Nakamura A, Yagishita S, et al. (1999)
Neuronal intranuclear inclusions in spinocerebellar ataxia type 2: triple-
labeling immunoﬂuorescent study. Neurosci Lett 273: 117–120.
48. Pang JT, Giunti P, Chamberlain S, An SF, Vitaliani R, et al. (2002) Neuronal
intranuclear inclusions in SCA2: a genetic, morphological and immuno-
histochemical study of two cases. Brain 125: 656–663.
49. Armstrong J, Bonaventura I, Rojo A, Gonzalez G, Corral J, et al. (2005)
Spinocerebellar ataxia type 2 (SCA2) with white matter involvement.
Neurosci Lett 381: 247–251.
50. Li SH, Li XJ (2004) Huntingtin and its role in neuronal degeneration.
Neuroscientist 10: 467–475.
51. Hackam AS, Hodgson JG, Singaraja R, Zhang T, Gan L, et al. (1999)
Evidence for both the nucleus and cytoplasm as subcellular sites of
pathogenesis in Huntington’s disease in cell culture and in transgenic mice
expressing mutant huntingtin. Philos Trans R Soc Lond B Biol Sci 354:
1047–1055.
52. Gunawardena S, Her LS, Brusch RG, Laymon RA, Niesman IR, et al. (2003)
Disruption of axonal transport by loss of huntingtin or expression of
pathogenic polyQ proteins in Drosophila. Neuron 40: 25–40.
53. Brand AH, Perrimon N (1993) Targeted gene expression as a means of
altering cell fates and generating dominant phenotypes. Development 118:
401–415.
54. Weihe U, Milan M, Cohen SM (2001) Regulation of Apterous activity in
Drosophila wing development. Development 128: 4615–4622.
55. Rual JF, Venkatesan K, Hao T, Hirozane-Kishikawa T, Dricot A, et al. (2005)
Towards a proteome-scale map of the human protein-protein interaction
network. Nature 437: 1173–1178.
PLoS Genetics | www.plosgenetics.org December 2007 | Volume 3 | Issue 12 | e234 2564
Ataxin-1 and Ataxin-2 Interactions